(Q37898014)

25 August 2017

1 reference

title

Membrane proteins: the key players of a cancer cell (English)

1 reference

25 August 2017

1 reference

1

Kim R Kampen

1 reference

25 August 2017

publication date

6 July 2011

1 reference

25 August 2017

number of pages

6

1 reference

Journal of Membrane Biology

inferred from page(s)

published in

1 reference

25 August 2017

volume

242

1 reference

25 August 2017

issue

2

1 reference

25 August 2017

page(s)

69-74

1 reference

Monitoring response and resistance to treatment in chronic myeloid leukemia

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

A phase 2 study of vatalanib in metastatic melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

The future of CD20 monoclonal antibody therapy in B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Specific visualization of glioma cells in living low-grade tumor tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Near-infrared pH-activatable fluorescent probes for imaging primary and metastatic breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

The prognostic role of a gene signature from tumorigenic breast-cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

TRIO-012: a multicenter, multinational, randomized, double-blind phase III study of IMC-1121B plus docetaxel versus placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast canc

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Development of EGFR-Targeted Polymer Blend Nanocarriers for Combination Paclitaxel/Lonidamine Delivery To Treat Multi-Drug Resistance in Human Breast and Ovarian Tumor Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

The prognostic significance of epidermal growth factor receptor expression in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Trastuzumab for gastric cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Isolation of a novel gene on 8p21.3-22 whose expression is reduced significantly in human colorectal cancers with liver metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Nanocarriers as an emerging platform for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

EGFR targeted fluorescence imaging in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

(-)-Epigallocatechin gallate inhibits growth and activation of the VEGF/VEGFR axis in human colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Opportunities and obstacles to combination targeted therapy in renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00232-011-9381-7

Loss of CD59 expression in breast tumours correlates with poor survival

21 January 2018

1 reference

12 December 2020

Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab

1 reference

12 December 2020

Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1

1 reference

12 December 2020

Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome

1 reference

12 December 2020

Potential mechanism of interleukin-8 production from lung cancer cells: an involvement of EGF-EGFR-PI3K-Akt-Erk pathway

1 reference

12 December 2020

Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up

1 reference

12 December 2020

Enhancing surgical vision by using real-time imaging of αvβ3-integrin targeted near-infrared fluorescent agent

1 reference

12 December 2020

Intraoperative imaging in ovarian cancer: fact or fiction?

1 reference

12 December 2020

Novel α(2)β(1) integrin-targeted peptide probes for prostate cancer imaging

1 reference

12 December 2020

10.1007/S00232-011-9381-7

Identifiers

DOI

1 reference

25 August 2017

1 reference